Burel Pharma

What Burel Pharma does

Burel Pharma is a privately held pharmaceutical distribution company that distributes generic specialty pharmaceuticals and provides related sourcing, sales, and distribution services. As described in its firmographic profile, the firm operates as an intermediary in the generic-drug supply chain, connecting upstream manufacturers with downstream buyers in the healthcare market. Its business model is consistent with a traditional B2B distribution intermediary — revenue would be generated through purchase-and-resale margins on distributed generic specialty products, supplemented by sourcing and sales services — though specific pricing mechanics, customer segments, contract structures, geographic markets, and go-to-market details are not disclosed in the available record.

The company maintains a web presence at burelpharma.com, but that property currently renders only a loading/verification screen ("One moment, please…" / "Please wait while your request is being verified…") with no substantive company content. Consequently, no financial data (revenue, funding, valuation), no headcount, no founding date, no ownership or investor information, no management team, no product portfolio specifics, no partnership or alliance disclosures, no certifications or regulatory filings, and no operating geographies are publicly available through the assembled source material. The company has confirmed no API, SDK, or integration surface, which is consistent with a traditional — rather than platform- or technology-enabled — distribution model.

No funding rounds, mergers, acquisitions, divestitures, product launches, leadership changes, restructuring actions, or other strategic moves are documented in the available record. The diligence posture for this company is therefore extremely data-thin: the only verified first-party statements are the company name, its self-description as a generic-specialty-pharmaceutical distributor offering sourcing/sales/distribution services, its private/for-profit status, and the absence of any developer-facing technical surface.

Name

Burel Pharma

Website

https://burelpharma.com

Company type

Private

Short description

Burel Pharma is a privately held pharmaceutical distribution firm that supplies generic specialty pharmaceuticals and offers related sourcing, sales, and distribution services to buyers operating across the healthcare market.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industries

Full-Line Pharmaceutical Wholesalers (HLAIAJAA), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

• Generic pharmaceutical distribution
• Specialty pharma sourcing
• Pharmaceutical sales services
• Drug distribution services
• Generic specialty medications

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Core offering

Burel Pharma distributes generic specialty pharmaceuticals. It also provides sourcing, sales, and distribution services to support the movement of these products to downstream buyers in the pharmaceutical supply chain.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic specialty pharmaceuticals distribution Distribution of generic specialty pharmaceuticals to downstream buyers in the pharmaceutical supply chain.
• Pharmaceutical sourcing, sales, and distribution services Sourcing, sales, and distribution services that support the movement of generic specialty pharmaceuticals to downstream buyers.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• McKesson Corporation: The largest U.S. pharmaceutical wholesaler with a dedicated McKesson Specialty division; a broad incumbent competing across the full specialty generics distribution market where Burel Pharma operates.
• Cencora (AmerisourceBergen): Major U.S. pharmaceutical wholesaler with a strong specialty distribution franchise (through US Bioservices and others); broad incumbent with overlapping capabilities to Burel Pharma's specialty generics focus.
• Cardinal Health: Top-tier U.S. pharmaceutical distributor with a Specialty Solutions segment covering specialty generics, oncology, and limited-distribution products; a direct incumbent competitor to a specialty generics distributor like Burel Pharma.

Direct peers

• H. D. Smith: Large privately held U.S. pharmaceutical wholesaler serving retail pharmacies, hospitals, and health systems; a direct peer with similar sourcing, sales, and distribution services for generic and specialty products.
• Smith Drug Company: Independent pharmaceutical wholesaler serving independent retail pharmacies and health systems with broad generic and branded lines; directly comparable in scale and business model to Burel Pharma.
• Morris & Dickson: Privately held U.S. pharmaceutical wholesaler focused on full-line and specialty distribution to pharmacies, hospitals, and health systems; one of the closest direct-peer comparables to a regional specialty generic distributor like Burel Pharma.
• Anda Inc: Specialty pharmaceutical distributor (historically part of Teva/Allergan) focused on generic and specialty products distributed to pharmacies and hospitals; a close functional peer to Burel Pharma's generic specialty distribution model.
• Northstar Healthcare Holdings: Specialty pharmaceutical distributor focused on sourcing hard-to-find and limited-distribution generics for hospitals and specialty pharmacies; a focused specialty peer to Burel Pharma's generic specialty distribution activities.

Regional players

• Rochester Drug Cooperative: Independent, member-owned pharmaceutical wholesaler serving pharmacies across the Northeast and Mid-Atlantic; a regional peer that competes for the same independent pharmacy and institutional customers as Burel Pharma.

Emerging players

• BluePoint Pharmaceuticals: Emerging specialty pharmaceutical distributor targeting independent pharmacies and physician offices with curated generic and specialty SKUs; an emerging peer with comparable business model but smaller scale than Burel Pharma.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat1 record

Key risks4 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Burel Pharma